{
    "id": 26088,
    "fullName": "PTK2B dec exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "PTK2B dec exp indicates decreased expression of the Ptk2b protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 2185,
        "geneSymbol": "PTK2B",
        "terms": [
            "PTK2B",
            "CADTK",
            "CAKB",
            "FADK2",
            "FAK2",
            "PKB",
            "PTK",
            "PYK2",
            "RAFTK"
        ]
    },
    "variant": "dec exp",
    "createDate": "02/28/2017",
    "updateDate": "12/01/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 10107,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knockdown of PTK2B in a triple-receptor negative breast cancer xenograft model harboring EGFR amplification enhanced treatment with Iressa (gefitinib), resulting in reduced tumor size and near complete tumor remission in some of the models (PMID: 27793840).",
            "molecularProfile": {
                "id": 27254,
                "profileName": "EGFR amp PTK2B dec exp"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8020,
                    "pubMedId": 27793840,
                    "title": "Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4-NDRG1 Axis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27793840"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 27254,
            "profileName": "EGFR amp PTK2B dec exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}